凌丹康复方配合DC-CIK治疗白血病临床观察

目的 观察中药凌丹康复方配合树突状细胞联合细胞因子诱导的杀伤细胞(DC CIK) 治疗白血病的临床效果和安全性。

Effect of Lingdankang Composite Combined Dendritic Cell-Cytokine Induced Killer Cells in Treating Leukemia

Objective To evaluate the effect and safety of Chinese herbal medicine Lingdankang Composite （LDK） combined dendritic cell-cytokine induced killer cells （DC-CIK） in treating leukemia. Methods Subjects were selected from leukemia patients who achieved hematological complete remission （HCR） but not achieved molecular biological remission （MBR）, or with minimal residual leukemia （MRL） positive. Twenty patients, 19 of acute leukemia and 1 of chronic myelocytic leukemia, were enrolled. DC and CIK from patient＇s peripheral blood monocyte were separated respectively by blood cell separator, then DC-CIK was obtained through respective culture followed with mixed cultivation of them, and was infused back to the patient self via intravenous injection. The back infusion of DC-CIK was performed once every 15-20 days for 4-6 times in total. Meantime, LDK was administered orally every day. Results In the 20 patients treated, 4 case of HCR achieved MBR, the negatively reversed marker gene was AML1/ETO in 1 case, CBFβ/MYH11 in 1, bcr/abl in 1, and the other 1 was IgH gene rearrangement; 3 patients with positive MRL were reversed to negative. The 3-year CR rate was 75% with a medium CR period of 25 months （10-37 months）. Except transient fever and chill in 5 cases, no other remarkable adverse reaction happened during or after DC-CIK infusion. Conclusion The combined treatment of LDK and autologous DC-CIK in treating patients with HCR shows an obvious effect of clearing MRL, it is the appropriate choice for curing leukemia of HCR, and is safety for intravenous infusion, so it has potential clinical prospect.